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Abstract
Background: The primary objective of this study was to determine the prevalence of neurocognitive impairment 
among HIV-positive individuals in Botswana, using the International HIV Dementia Scale (IHDS). We also compared 
performance on the IHDS with performance on tests of verbal learning/memory and processing speed, and 
investigated the association between performance on the IHDS and such variables as depression, age, level of 
education and CD4 count.
Methods: We conducted a cross-sectional study of 120 HIV-positive individuals randomly selected from an outpatient 
HIV clinic in Gaborone, Botswana. Patients provided a detailed clinical history and underwent neuropsychological 
testing; measures of depression, daily activities and subjective cognitive complaints were recorded.
Results: Despite the fact that 97.5% of subjects were receiving highly active antiretroviral therapy (HAART), 38% met 
criteria for dementia on the IHDS, and 24% were diagnosed with major depressive disorder. There was a significant 
association between neurocognitive impairment as measured by the IHDS and performance on the other two 
cognitive measures of verbal learning/memory and processing speed. Level of education significantly affected 
performance on all three cognitive measures, and age affected processing speed and performance on the IHDS. 
Depression and current CD4 count did not affect performance on any of the cognitive measures.
Conclusions: The prevalence of neurocognitive impairment in HIV-positive individuals in Botswana is higher than 
expected, especially since almost all of the subjects in this study were prescribed HAART. This suggests the need to 
reconsider the timing of introduction of antiretroviral therapy in developing countries where HAART is generally not 
administered until the CD4 cell count has dropped to 200/mm3 or below. The contribution of other factors should also 
be considered, such as poor central nervous system penetration of some antiretrovirals, drug resistance, potential 
neurotoxicity, and co-morbidities. Memory impairment and poor judgment may be underlying causes for behaviours 
that contribute to the spread of HIV and to poor adherence. It is important to identify these neurobehavioural 
complications of HIV so that effective treatments can be developed.
Background
Individuals with HIV infection often experience neuro-
logical complications, including cognitive deficits,
referred to as HIV-associated neurocognitive disorders
(HAND). The specific pattern of neuropsychological def-
icits is attributed to damage to the fronto-striatal cir-
cuitry, which is commonly observed in HIV infection [1-
3].
In recent years, HIV-related neurological disease has
been increasingly recognized in resource-limited set-
tings. One of the first multi-centre international studies
was carried out with HIV-positive symptomatic and
asymptomatic patients and HIV-negative subjects by the
World Health Organization (WHO) in five countries:
Thailand, Zaire, Kenya, Brazil, and Germany. Researchers
found that neuropsychological impairment of symptom-
atic HIV-positive individuals ranged from 13% in Brazil
to 19% in Zaire [4].
Since this study, there has been growing concern about
the impact of HIV subtypes on disease progression. In
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Page 2 of 9Uganda, where clades A and D are the predominant sub-
types, 31% of HIV-positive subjects met criteria for
dementia, 47% mild cognitive impairment, and 22% no
impairment on neuropsychological testing. The authors
concluded that HIV dementia in the Uganda sample
might be similar to the frequency of HIV dementia in the
US in the pre-highly active antiretroviral therapy
(HAART) era [5]. A follow-up study in Uganda of the risk
factors for developing HAND demonstrated that
advanced age and low CD4+ T cell count were the main
risk factors for dementia [6].
However, some researchers have suggested that the
incidence of HIV dementia may vary due to different viral
clades [7]. For example, a study in Ethiopia evaluated the
neurological complications of HIV (clade C) in HAART-
naïve patients compared with matched HIV-negative
controls and did not find impairment on the Interna-
tional HIV Dementia Scale (IHDS), which led the authors
to hypothesize that HIV-related dementia may vary due
to different viral clades [8]. In contrast, the Australia-
Pacific NeuroAIDS Consortium found substantial neu-
rocognitive and motor impairment in clade C HIV-posi-
tive subjects in several countries in the Pacific Rim.
Timed gait was impaired in 28%, with impairment for
verbal fluency in 33.6%, grooved peg board in 14%, and
finger tapping in 43% [9].
Similarly, a study of HIV-positive subjects in southern
India, where clade C is most common, found 60.5% had
mild to moderate cognitive deficits in the domains of ver-
bal fluency, working memory, and learning/memory in
subjects who did not have clinically identifiable func-
tional impairment [10]. Most recently, a study in China
found neuropsychological impairment in 34.2% of HIV-
positive subjects, and in 39.7% of HIV-positive subjects
coinfected with the hepatitis C virus [11]. The authors
concluded that the prevalence, severity and pattern of
cognitive impairment were similar to those reported by
western studies. A preliminary study addressing the
effect of HAART on neurological function in Uganda
found that HIV dementia improved from 61% at baseline
to only 4% after six months of HAART [12].
Cognitive impairment and depression frequently coex-
ist in HIV [13]. Despite this, few neuropsychological
studies of HIV-positive individuals in developing coun-
tries have included adequate measures of depression.
Depression can adversely influence performance on cog-
nitive tests due to poor effort, slowed processing speed,
psychomotor retardation, or a combination of these fac-
tors [14]. The IHDS may be particularly vulnerable to the
effects of depression since two of the three subtests have
time limits designed to measure speed of information
processing and motor speed.
To address these questions, this preliminary study
focused on three objectives. The first was to explore the
use of the IHDS in HIV-positive individuals in Botswana
to measure the prevalence of neurocognitive impairment.
Recent guidelines [15] support the use of standardized
mental status examinations, such as the IHDS [16], to
diagnose HAND in regions where neuropsychological
testing is not available. The second objective was to com-
pare performance on the IHDS with performance on the
most sensitive test combination for detecting HAND,
verbal learning/memory and processing speed [17]. The
third was to explore the association between perfor-
mance on the IHDS and important variables, such as
depression, age, education and current CD4 count.
Methods
Participants were 120 randomly selected HIV-positive
subjects (60 women and 60 men). They were asked to
participate in this study during routine follow-up visits
from March to May 2008 at the Infectious Disease Care
Clinic at Princess Marina Hospital, a 550-bed tertiary
referral hospital in Gaborone, which serves southern
Botswana. Control subjects were not included because
this pilot study was focused on determining the feasibility
of adapting and validating neuropsychological tests and
depression inventories used in developed countries for
HIV-infected individuals in Botswana. No reimburse-
ment for participation was offered.
Inclusion criteria were: (1) documented HIV-positive
status; (2) age of 21-50; (3) ambulatory status; (4) the abil-
ity to comprehend study procedures; and (5) provision of
informed consent. Consistent with current treatment
practices in Botswana at the time of this study, subjects
started treatment with HAART when their CD4 cell
count dropped to 200/mm3 or below. Thus, most patients
in this study had a history of very low CD4 counts since
97.5% were prescribed HAART.
Exclusion criteria eliminated individuals with cognitive
impairment unrelated to HIV, such as: (1) neurological
conditions (e.g., head injury, seizure disorder); (2) medi-
cal illness unrelated to HIV (e.g., chronic hepatic or renal
failure, malignancy) or severe HIV-related disease (cur-
rent opportunistic infection); (3) current fever; (4) severe
psychiatric disorder (e.g., schizophrenia); (5) a history of
substance abuse; and (6) inability to function indepen-
dently.
Procedure
Participants underwent a standardized neuropsychologi-
cal examination and assessment of depression, activities
of daily functioning, and subjective cognitive complaints.
Details of the depression findings are reported elsewhere
[18]. Assessments were carried out by Botswana nursing
staff and neuropsychology researchers from the Univer-
sity of Pennsylvania. Testing procedures were standard-
ized across examiners; the neuropsychology expert
Lawler et al. Journal of the International AIDS Society 2010, 13:15
http://www.jiasociety.org/content/13/1/15
Page 3 of 9observed all examiners in training prior to test adminis-
tration to subjects.
Structured interviews and chart reviews were per-
formed to obtain information about medical and psychi-
atric history, pattern of substance use, marital status,
education, current medications, recent CD4 counts and
viral loads. Viral load testing was performed using the
Amplicor HIV-1 Monitor Test (Roche Molecular Sys-
tems, Branchburg, New Jersey). Viral load measurements
have been categorized dichotomously (detectable vs.
undetectable) using a threshold of 400 copies/ml. The
investigators evaluated neuropathy using a targeted his-
tory composed of structured validated questions
designed to elicit symptoms of distal sensory loss or pain.
This research study was approved by the Institutional
Review Boards of the Botswana Ministry of Health, Prin-
cess Marina Hospital, and the University of Pennsylvania.
All consent forms, questionnaires, and tests were trans-
lated into Setswana and back translated. For patients with
limited reading ability, the examiners orally administered
the Activities of Daily Living (ADL) Scale.
Measures
The test battery was selected to assess multiple cognitive-
motor ability domains that have repeatedly been shown
to be affected by HIV-associated brain disease in both
developed and developing countries.
International HIV Dementia Scale
The IHDS is a screening measure of neurocognitive
impairment that includes: memory registration for four
common objects; motor speed involving the rapid tap-
ping of the thumb and first digit of the non-dominant
hand; speed of information processing and/or executive
functioning measured by repetition of a three-position
alternating hand sequence; and memory recall of the four
objects [16]. A prior study in Uganda determined the
optimal cut-off value for the IHDS. The cut-off value of
9.5 maximized the sensitivity (71%) and specificity (79%)
for HIV dementia, and thus was chosen for our current
study. This cut-off score has been recommended to mini-
mize false positives errors [16].
World Health Organization-University of California Auditory 
Verbal Learning Test
The World Health Organization-University of California
Auditory Verbal Learning Test (AVLT) is a list-learning
task that assesses verbal learning and memory with 15
words carefully selected to be familiar in most cultures
[19]. Scores include the total number of words learned for
all five trials (TL), delayed recall (DR), and recognition of
the words (R).
Wechsler Adult Intelligence Scale (third edition) Digit Symbol 
Coding
The Digit Symbol (DS) Coding is a paper-pencil measure
of processing speed in which subjects use a key of digit-
symbol pairs at the top of the test page and are required
to fill in the correct symbol for each number as quickly as
possible within a 120-second time limit. The score is the
number of correct items completed within the time limit
[20].
Mood Module of the primary care evaluation of mental 
disorders
The Mood Module (MM) [21] is a focused interviewing
guide that follows the Diagnostic and Statistical Manual-
IV (DSM-IV) criteria [22] for screening medical patients
for current depression. It is composed of simple "yes" and
"no" questions. If five or more of the nine symptoms are
present and one of these symptoms is sadness/hopeless-
ness or anhedonia, then a diagnosis of major depressive
disorder (MDD) is supported. The MM has been success-
fully used to diagnose depression in patients with HIV
and was found to have a sensitivity of 77% and specificity
of 84% [23].
Activities of Daily Living Scale
This questionnaire was adapted from the original mea-
sure and selected for its wide use and demonstrated valid-
ity in studies of medically ill and dementia populations,
including HIV [24]. It is a 14-item scale measuring physi-
cal self-maintenance activities (e.g., dressing, bathing)
and instrumental activities of daily living (e.g., preparing
meals, taking medications). Each item is rated on a four-
point scale: (1) no difficulty at all; (2) has some difficulty;
(3) needs some assistance; or (4) can't do at all. Thus,
higher scores indicate more impairment in daily func-
tioning. The modified version used in this study was used
and validated in studies of HIV subjects [25].
Subjective Cognitive Complaints questionnaire
This is a brief self-report questionnaire of subjective cog-
nitive complaints with specific items for four cognitive
domains: memory, concentration, speech and thinking.
This simple questionnaire asked patients to rate the
amount of difficulty they were experiencing on a scale of
0 to 2, as follows: 0 no problem; 1 yes, but currently
absent; 2, yes, currently present. Scores for each cognitive
domain were added together for a total subjective cogni-
tive score, with a maximum possible score of 8. This
questionnaire was previously used in a cross-cultural
study that assessed cognitive complaints in HIV-positive
individuals in five different countries [4].
Data analysis
We performed descriptive analyses and comparisons to
examine the demographic and clinical characteristics of
patients. All analyses were conducted using StataMP 10.0
(Stata Corp., College Station, Texas). Correlation coeffi-
cients were used to assess relationships between continu-
ous variables. Student's t-tests and analysis of variance
were used for comparisons of normally distributed vari-
ables. Kruskal-Wallis rank was used for non-normal vari-
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variables. The relative importance of dementia on cogni-
tive outcomes, adjusted for demographic (age, race, gen-
der, education, language of test administration,
depression), and HIV (current CD4 count, time since
beginning HAART, a detectable viral load) characteris-
tics, was assessed using regression models. As this was an
exploratory study, alpha was set at 0.05 to determine sta-
tistical significance.
Results
Demographic and clinical characteristics of the cohort
are described in Table 1.
International HIV Dementia Scale
Using a cut-off score of 9.5 or less on the IHDS, 38% of
the patients met criteria for neurocognitive impairment
(Table 2). Subjects diagnosed with neurocognitive
impairment on the IHDS had lower scores on the AVLT
for both TL (p = 0.023) and DR (p = 0.026), but not for R
(p = 0.897). Similarly, those classified with neurocognitive
impairment on the IHDS had slower processing speed on
the Digital Symbol (DS) coding (p < 0.001).
Current CD4 count (p > 0.445), gender (p = 0.556), sub-
stance use (p = 0.194) and employment status (p = 0.419)
were not associated with neurocognitive impairment.
Language of test administration was not associated with
performance on the IHDS (p = 0.613). There was no asso-
ciation between peripheral neuropathy and neurocogni-
tive impairment (p = 0.389). In addition, there was no
association between neurocognitive impairment and
length of time since HIV diagnosis (p = 0.528). However,
subjects with neurocognitive impairment had been pre-
scribed HAART for longer than those without impair-
ment (p = 0.026).
Subjects classified with neurocognitive impairment
were characterized by increased age (p = 0.008) and had
fewer years of education (p = 0.035). Looking at the three
subtests of the IHDS, increased age (p = 0.039) and those
with less years of education (p = 0.002) had slower motor
speed (finger tapping). Similarly, information processing
speed (serial hand positions, p = 0.005) was adversely
affected by increasing age (as subjects became older, they
were slower), but level of education did not affect perfor-
mance on this subtest (p = 0.195). Performance on the
memory subtest was not associated with age (p = 0.381)
or education (p = 0.778). Because of the effect of educa-
tion, we re-analyzed the IHDS data excluding subjects
with no education. With this adjustment, 35% of subjects
met criteria for neurocognitive impairment.
MDD was diagnosed with the MM in 24% of subjects,
but depression was not significantly associated with the
total score on the IHDS (p = 0.620) or scores on any of the
subtests of the IHDS (motor speed p = 0.448, psychomo-
tor speed p = 0.973, memory p = 0.803).
Auditory Verbal Learning Test
Age was not significantly associated with verbal leaning/
memory with the AVLT (TL p = 0.460, DR p = 0.841, R p
= 0.245). Similarly, gender (TL p = 0.291, DR p = 0.533, R
p = 0.340), substance use (TL p = 0.084, DR p = 0.678, R p
= 0.555), employment status (TL p = 0.786, DR p = 0.469,
R p = 0.149), CD4 count (TL p = 0.747, DR p = 0.674, R p
= 0.165), time since beginning HAART (TL p = 0.313, DR
p = 0.81, R p = 0.395), and depression (TL p = 0.604, DR p
= 0.852, R p = 0.553) were not associated with verbal
learning/memory.
Level of education was not associated with total learn-
ing (TL) on the AVLT (p = 0.758), but was significant for
delayed recall (DR) (p = 0.027) and did not quite reach
statistical significance for recognition (R) (p = 0.053).
Language of test administration was not associated with
AVLT TL (p = 0.065), but those tested in Setswana had
higher DR scores (p < 0.001), and subjects tested with a
combination of both languages had lower R scores than
those tested in either English or Setswana alone (R p =
0.009).
In fully adjusted analyses (all demographic and HIV
characteristics) for AVLT TL, neurocognitive impairment
did not reach statistical significance (b = -3.79, p = 0.064).
However, due to the limited sample size in this pilot
study, we also reduced the final model down to only sig-
nificant effects. In this final model, neurocognitive
impairment and language of test administration were sig-
nificantly associated with AVTL TL. Subjects with neu-
rocognitive impairment tended to have four-point lower
TL scores (b = -4.13, p = 0.013), while subjects tested in
English had four-point lower TL scores than subjects
tested in Setswana (b = -4.35, p = 0.011).
In fully adjusted models for AVLT DR, both neurocog-
nitive impairment and language of test administration
still significantly impacted the scores. Subjects with neu-
rocognitive impairment tended to have 1.5-point lower
DR scores (b = -1.48, p = 0.015), while subjects tested in
English had two-point lower DR scores than subjects
tested in Setswana (b = -1.64, p = 0.032).
Digit Symbol Coding subtest
There was an inverse relationship between a subject's age
and processing speed (Digital Symbol, DS); as the sub-
jects' ages increased, they performed significantly slower
than their younger counterparts (p < 0.001). Similarly,
subjects with less years of education were also slower (p <
0.001); for each additional year of education, subjects
completed an average of 2.3 additional items. Males were
significantly slower than females (p = 0.032), and subjects
tested in Setswana were slower than subjects tested in
either English (p < 0.001) or both English and Setswana (p
< 0.001).
Processing speed was not affected by substance use (p =
0.194), employment status (p = 0.470), CD4 count (p =
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Table 1: Demographic and clinical characteristics of subjects (n = 120).




HIV-POSITIVE SUBJECTS (n = 120)
Age (years) 37.5 6.5 23 - 50
Education (years) 8.9 4.1 0 - 18
No education 8%
Primary (1-7 yrs) 29%
Secondary (8-12 yrs) 48%
Post-secondary (>12 yrs) 15%
Gender (female) 50%
CD4 count 360.4 181.4 42 - 881.8
Subjects with CD4 <200/mm3 20% 149.2 44.2 42 - 199.4
Viral load
<400 copies/mL 80%
>400 copies/mL 17% 37,181.0 92,828.2 490 - 270,000
Unknown 3%
Time since HIV-positive diagnosis 
(years)
3.9 2.4 <1 - 14
On HAART (≥ 3 drugs) 97.5%
Time since beginning HAART 
(years)
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addition, there was no observed association between pro-
cessing speed and depression (p = 0.345). Twenty-six per-
cent of subjects reported symptoms of peripheral
neuropathy, but there was no association between those
with and without these symptoms for processing speed
on the DS (p = 0.865).
In fully adjusted models, neurocognitive impairment
and education were the only characteristics associated
with DS. Subjects with fewer years of education were
slower, with a decrease of two points for each year of
missed education (b = 1.76, p < 0.001). Subjects with neu-
rocognitive impairment had DS scores that were seven
points lower on average than subjects without neurocog-
nitive impairment (b = -6.80, p = 0.004).
Activities of Daily Living Scale and Subjective Cognitive 
Complaints questionnaire
Individuals who met criteria for a MDD on the MM
reported greater levels of impairment (p = 0.044) on the
ADL Scale, but classification of neurocognitive impair-
ment with the IHDS was not related to ADL scores (p =
0.334). Similarly, speed of information processing (DS p =
0.395) and learning/memory (TL p = 0.082, DR p = 0.275,
R p = 0.188) were not associated with ADL scores. There
was no association between the ADL score and CD4 level
(p = 0.949), age (p = 0.482) or education (p = 0.081). Sim-
ilarly, there was no significant association between neu-
rocognitive impairment and subjective cognitive
complaints (total score, p = 0.920).
Viral loads
Eighty percent of subjects in our sample did not have a
detectable viral load (i.e., below the detection limit of 400
copies/mL). Thus, it was not feasible to analyze the data
as a continuous outcome. We did look at viral load as a
dichotomous outcome of yes/no detectable viral load.
However, there were no significant associations with this
variable, even at a bivariate level.
Discussion
The prevalence of neurocognitive impairment in our
study was higher than anticipated. Most of our subjects
were receiving treatment with HAART, thus we did not
expect so many to meet criteria for neurocognitive
impairment on a screening measure, such as the IHDS.
Yet it is important to note that the high prevalence of
neurocognitive impairment in this study may reflect our
use of a tool, such as the IHDS, which requires further
refinement. Given the association between demographic
variables and performance on the IHDS, future studies in
Botswana should establish demographically adjusted nor-
mative standards for the IHDS, as has been done for a
similar screening measure, the HIV Dementia Scale, in
the United States [26].
A study in Uganda using the IHDS found HIV dementia
in 31% of subjects, but in that study, less subjects were
receiving antiretroviral treatment [16]. Furthermore,
another recent study in Uganda demonstrated significant
improvement in cognitive functioning after the initiation
of HAART [12]. Different viral clades may account for the
variation in the incidence of dementia in geographic dis-
tinct regions of Africa. Certain clades may be more or less
neuropathogenic [27,28].
For example, in Ethiopia, the IHDS did not detect
impairment in untreated HIV-positive subjects, and Clif-
ford et al hypothesized that clade C virus, which is most
prevalent in Ethiopia, may be less neurotropic than clades
A and D, which are predominant in Uganda [8]. However,
the researchers in Ethiopia modified the IHDS memory
sub-test stimuli, which may have affected the sensitivity
of the test. In addition, subjects in the Ethiopian study
were recruited from the community, rather than from an
Table 2: Mean scores and standard deviation (in parentheses) for the two cognitive tests, Auditory Verbal Learning (AVL) 
Test and Total Learning (TL) score, and Digit Symbol (DS) Coding (number of items correctly completed within the time 
limit), for subject groups classified with and without neurocognitive impairment (IHDS cut-off score of ≤ 9.5).
SUBJECTS NOT IMPAIRED 
WITH IHDS (62%)





WHO Auditory Verbal 
Learning Test (AVLT) (Total 
Learning, TL)
47.61 (9.11) 43.78 (8.42) p = 0.023
Digit Symbol Coding (DS)
(items completed correctly 
within time limit)
41.79 (14.47) 30.40 (11.98) p < 0.001
Lawler et al. Journal of the International AIDS Society 2010, 13:15
http://www.jiasociety.org/content/13/1/15
Page 7 of 9HIV clinic, and therefore may have been healthier than
the subjects in the Uganda study and those in our study.
Furthermore, the relatively high prevalence of neu-
rocognitive impairment in HIV-positive subjects found in
our Botswana study, a region where clade C HIV predom-
inates, is consistent with several Pacific Rim studies.
Authors of one Pacific Rim study concluded that that
clade C HIV is no less neurotropic than other clades [9].
In addition, a neuropsychological study in southern India
of clade C-infected HIV-positive subjects found mild to
moderate cognitive impairment in 60% of subjects who
did not have any clinically identifiable functional impair-
ment [10].
Neurocognitive impairment and depression are inde-
pendent complications of HIV. For example, although
24% of our subjects were diagnosed with MDD, depres-
sion did not affect the total score or any of the three sub-
test scores of the IHDS. Similarly, depression was not
significantly associated with verbal learning/memory (the
AVLT) or processing speed (DS Coding), which is consis-
tent with prior studies showing that depression and cog-
nitive impairment are independent in HIV [29,30].
Furthermore, subjects classified with neurocognitive
impairment using the IHDS were basically asymptomatic
since they did not report problems with daily activities or
complain of cognitive problems. This was consistent with
the examiners' observations that the majority of patients
were independent, with minimal functional limitations or
complaints. In addition, 68% of subjects reported being
gainfully employed.
The results of our study may have implications for
when it is best to start HIV therapy. The number of years
since HIV diagnosis was not a significant predictor for
neurocognitive impairment. However, the longer a sub-
ject was prescribed HAART, the more likely he or she was
to be diagnosed with neurocognitive impairment. Persis-
tent cognitive deficits in HAART-treated subjects may be
a result of pre-treatment neurological damage, poor cen-
tral nervous system penetration of some antiretroviral
agents, drug resistance, poor adherence, potential neuro-
toxicity, and co-morbidities [31]; future prospective stud-
ies in Botswana will need to clarify these issues.
Continuous viral loads should generally be log-trans-
formed in order to meet normal assumptions, but in our
sample, 80% did not have a detectable viral load (i.e.,
below the detection limit). Thus, it was not feasible to
analyze the data as a continuous outcome. We did look at
viral load as a dichotomous outcome of yes/no detectable
viral load, but there were no significant associations with
this variable even at a bivariate level.
The finding that current CD4 count was not associated
with performance on the IHDS or the other two cognitive
tests was expected, since most of the subjects were
receiving HAART. Studies in the HAART era have shown
that biomarkers, such as current CD4 count, plasma viral
load, CSF viral load and CSF immune markers, are not
correlated with, or predictive of, neurocognitive impair-
ment [32]. Recent research has suggested that cognitive
impairment may become more likely the lower the value
of the nadir CD4 cell count [11,33,34]. Nadir CD4 cell
count was not available for our subjects, but should be
included in future research in Botswana.
The IHDS has the potential to be a useful screening
instrument for HIV-associated neurocognitive disorders
(HAND). As anticipated, subjects who were classified
with neurocognitive impairment on the IHDS also per-
formed significantly lower on other tests of cognitive
function, specifically processing speed (DS Coding) and
verbal learning/memory (the AVLT). On a cautionary
note, it is sobering that several variables also affected per-
formance on the IHDS and the two other cognitive mea-
sures. For example, language of test administration was
related to performance on tests of both verbal memory
(AVLT) and processing speed (DS), which may be related
to cultural factors or socio-economic status, and requires
further investigation.
Even though there was a relatively small range of ages in
our sample, age adversely affected performance on the
IHDS. Similarly, education was associated with perfor-
mance on the IHDS. Older and less educated subjects
obtained significantly lower scores on the IHDS. Perfor-
mance on most mental status examinations does not
depend on processing or motor speed, but speed is a
major component of two of the three IHDS subtests; thus
performance is particularly vulnerable to the effects of
age and education. This highlights the need to take these
factors into account when determining local normative
cut-off scores for screening tests of HIV dementia [26].
Our results support the hypothesis that memory
impairment in HIV infection is caused by disruption of
subcortical processes. This is reflected in impaired free
recall due to retrieval inefficiencies, but relatively pre-
served recognition. Subjects meeting criteria for neu-
rocognitive impairment on the IHDS performed poorly
on the learning/memory test (AVLT) for both total learn-
ing (TL) and delayed free recall (DR), but not recognition
(R). This is consistent with the neuropsychological pat-
tern of memory deficits documented in prior studies of
HAND, characterized by impaired learning and retrieval,
but intact recognition [35-37].
This pilot study has several limitations: the absence of
an HIV-negative control group for comparison; symp-
toms of peripheral neuropathy being elicited by a tar-
geted clinical history and not by examination; and the
study being conducted among HIV-positive patients in
an urban outpatient HIV clinic in Botswana, which may
not be representative of HIV-positive individuals in com-
munity and rural settings. In addition, appropriate demo-
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possible learning effects with repeated screenings are
needed for the IHDS before it can be used confidently to
classify HAND in individuals in Botswana.
Conclusions
More than one-third of HIV-positive subjects met crite-
ria for neurocognitive impairment with the IHDS, despite
the fact that almost all were treated with HAART for an
average of two years and were asymptomatic from the
perspective of subjective complaints and everyday activi-
ties. This finding, combined with recent research indicat-
ing that cognitive impairment may become more likely
the lower the value of the nadir CD4 cell count, gives fur-
ther weight to the importance of initiating treatment with
HAART at earlier stages of the disease process.
In addition, there may be more than one explanation
for the persistence of neurocognitive deficits, with differ-
ent policy implications. These include: treatment regi-
men, particularly poor central nervous system
penetration of some antiretrovirals; drug resistance; poor
adherence; potential neurotoxicity; and co-morbidities,
such as long-term cardiovascular disease side effects of
HAART, and chronic HIV brain infection. Our results,
while admittedly tentative, indicate that neurocognitive
impairment is likely to be an important component of
HIV infection in developing countries, and highlight the
need to develop effective treatments.
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